Cargando…

Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype

The vascular endothelial growth factor (VEGF) pathway is a clinically validated antiangiogenic target for non-small cell lung cancer (NSCLC). However, some contradictory results have been reported on the biological effects of antiangiogenic drugs. In order to evaluate the efficacy of these drugs in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larrayoz, Marta, Pio, Ruben, Pajares, María J, Zudaire, Isabel, Ajona, Daniel, Casanovas, Oriol, Montuenga, Luis M, Agorreta, Jackeline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Backwell Publishing Ltd 2014
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992079/ https://www.ncbi.nlm.nih.gov/pubmed/24500694 http://dx.doi.org/10.1002/emmm.201303214

Ejemplares similares

Expression of Sirtuin 1 and 2 Is Associated with Poor Prognosis in Non-Small Cell Lung Cancer Patients
por: Grbesa, Ivana, et al.
Publicado: (2015)

VEGF(121)b and VEGF(165)b are weakly angiogenic isoforms of VEGF-A
por: Catena, Raúl, et al.
Publicado: (2010)

Combined clinical and genomic signatures for the prognosis of early stage non-small cell lung cancer based on gene copy number alterations
por: Aramburu, Ander, et al.
Publicado: (2015)

Complement C4d-specific antibodies for the diagnosis of lung cancer
por: Ajona, Daniel, et al.
Publicado: (2017)

Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
por: Valencia, Karmele, et al.
Publicado: (2022)

Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens
por: Nguewa, Paul A, et al.
Publicado: (2008)

TGFBI expression is associated with a better response to chemotherapy in NSCLC
por: Irigoyen, Marta, et al.
Publicado: (2010)

Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
por: Hsu, Yi-Fan, et al.
Publicado: (2010)

TGFBI expression is an independent predictor of survival in adjuvant-treated lung squamous cell carcinoma patients
por: Pajares, M J, et al.
Publicado: (2014)

Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer
por: Pio, Ruben, et al.
Publicado: (2010)

Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology
por: Larzabal, L, et al.
Publicado: (2011)

The sVEGFR1-i13 splice variant regulates a β1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma
por: Abou Faycal, Cherine, et al.
Publicado: (2018)

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
por: Redin, Esther, et al.
Publicado: (2021)

Identification of Novel Deregulated RNA Metabolism-Related Genes in Non-Small Cell Lung Cancer
por: Valles, Iñaki, et al.
Publicado: (2012)

The diverse lives of TRAP1
por: Agorreta, Jackeline, et al.
Publicado: (2014)

Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
por: Ajona, Daniel, et al.
Publicado: (2015)

Complement in Metastasis: A Comp in the Camp
por: Ajona, Daniel, et al.
Publicado: (2019)

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
por: Jiménez-Valerio, Gabriela, et al.
Publicado: (2016)

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy
por: Ebos, John ML, et al.
Publicado: (2014)

The Complement System in Ovarian Cancer: An Underexplored Old Path
por: Senent, Yaiza, et al.
Publicado: (2021)

Molecular biomarkers in early stage lung cancer
por: Rodríguez, María, et al.
Publicado: (2021)

Advances in antiangiogenic treatment of small-cell lung cancer
por: Lu, Hongyang, et al.
Publicado: (2017)

Kidney cancer PDOXs reveal patient‐specific pro‐malignant effects of antiangiogenics and its molecular traits
por: Moserle, Lidia, et al.
Publicado: (2020)

Complementing the Cancer-Immunity Cycle
por: Pio, Ruben, et al.
Publicado: (2019)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma
por: Vallejo-Díaz, Jesús, et al.
Publicado: (2016)

Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
por: Haidl, Friederike, et al.
Publicado: (2017)

Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography
por: Zhu, Xiao-Dong, et al.
Publicado: (2011)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Antiangiogenic Effect of Alkaloids
por: Alasvand, Masoud, et al.
Publicado: (2019)

Antiangiogeneic Strategies in Mesothelioma
por: Nowak, Anna K., et al.
Publicado: (2020)

Naked Cuticle Drosophila 1 Expression in Histologic Subtypes of Small Adenocarcinoma of the Lung
por: Ahn, Sangjeong, et al.
Publicado: (2013)

Subtyping non-small cell lung cancer by histology-guided spatial metabolomics
por: Neumann, Judith Martha, et al.
Publicado: (2021)

Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI
por: Cho, Hye Rim, et al.
Publicado: (2019)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

Diclofenac Loaded Biodegradable Nanoparticles as Antitumoral and Antiangiogenic Therapy
por: Esteruelas, Gerard, et al.
Publicado: (2022)

Novel production method of innovative antiangiogenic and antitumor small peptides in Escherichia coli
por: Setrerrahmane, Sarra, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mfl2i2f1ub0tfs3h8euaadajn1